Cancer Genetics and Kreatech form cancer deal
This article was originally published in Clinica
Executive Summary
Cancer Genetics and Dutch firm Kreatech Biotechnology have signed a deal to commercialise novel DNA probe assays for diagnosing and monitoring cancer. Under the conditions of the licence & product supply agreement, CGI's novel DNA preparation and probes for detecting and monitoring haematopoietic malignancies is being combined with Kreatech's Universal Linkage System (ULS) labelling technology to produce ULS-labelled DNA probes for fluorescent in situ hybridisation analyses. Cambridge, Massachusetts-based CGI plans to start selling the probes in Europe in the fourth quarter of 2002 and in the Asian and US markets in early 2003.